SEC Form 4 · accession 0001193125-26-295090
Kymera Therapeutics, Inc. · KYMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce N. Jacobs
Officer — Chief Financial Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 6:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001815442
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 30, 2026 | M | 61,378 | $5.33 | A | 321,992 | D | |
| Common StockF3 | Jun 30, 2026 | S | 1,500 | $110.5397 | D | 320,492 | D | |
| Common StockF4 | Jun 30, 2026 | S | 1,700 | $111.5671 | D | 318,792 | D | |
| Common StockF5 | Jun 30, 2026 | S | 1,100 | $112.7881 | D | 317,692 | D | |
| Common StockF6 | Jun 30, 2026 | S | 4,110 | $114.1875 | D | 313,582 | D | |
| Common StockF7 | Jun 30, 2026 | S | 51,375 | $114.7696 | D | 262,207 | D | |
| Common StockF8 | Jun 30, 2026 | S | 7,971 | $115.8171 | D | 254,236 | D | |
| Common StockF9 | Jun 30, 2026 | S | 6,153 | $116.9937 | D | 248,083 | D | |
| Common StockF10 | Jun 30, 2026 | S | 3,200 | $117.7029 | D | 244,883 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F11 | $5.33 | Jun 30, 2026 | M | 61,378 | D | — | May 13, 2030 | Common Stock | 61,378 | 0 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person.
- F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 to $118.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F11The shares underlying this stock option are fully vested and exercisable.
- F2This number includes 373 shares acquired under the Registrant's employee stock purchase plan.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.37 to $110.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.41 to $112.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.49 to $113.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.49 to $114.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.49 to $115.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.49 to $116.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.